MX2023001567A - Metodos de preparacion de nanoparticulas lipidicas. - Google Patents
Metodos de preparacion de nanoparticulas lipidicas.Info
- Publication number
- MX2023001567A MX2023001567A MX2023001567A MX2023001567A MX2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lipid nanoparticles
- preparing lipid
- lnp
- formulations
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062369P | 2020-08-06 | 2020-08-06 | |
| US202163143703P | 2021-01-29 | 2021-01-29 | |
| US202163226395P | 2021-07-28 | 2021-07-28 | |
| PCT/US2021/044928 WO2022032087A1 (en) | 2020-08-06 | 2021-08-06 | Methods of preparing lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001567A true MX2023001567A (es) | 2023-06-28 |
Family
ID=77519867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001567A MX2023001567A (es) | 2020-08-06 | 2021-08-06 | Metodos de preparacion de nanoparticulas lipidicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277457A1 (https=) |
| EP (1) | EP4192432A1 (https=) |
| JP (1) | JP2023543963A (https=) |
| KR (1) | KR20230167008A (https=) |
| AU (1) | AU2021322310A1 (https=) |
| BR (1) | BR112023002071A2 (https=) |
| CA (1) | CA3190790A1 (https=) |
| IL (1) | IL300404A (https=) |
| MX (1) | MX2023001567A (https=) |
| TW (1) | TW202220637A (https=) |
| WO (1) | WO2022032087A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
| US20250375389A1 (en) | 2022-07-29 | 2025-12-11 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| KR20250129818A (ko) * | 2022-12-01 | 2025-08-29 | 제너레이션 바이오 컴퍼니 | 합성 단일-가닥 dna 분자 및 이를 생산하고 사용하는 방법 |
| WO2024160826A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| CN115844833A (zh) * | 2023-02-14 | 2023-03-28 | 武汉载元生物科技有限公司 | 一种可电离脂质纳米粒及其制备方法 |
| EP4683666A1 (en) | 2023-03-23 | 2026-01-28 | ModernaTX, Inc. | Peg targeting compounds for delivery of therapeutics |
| WO2024197310A1 (en) | 2023-03-23 | 2024-09-26 | Modernatx, Inc. | Peg targeting compounds for delivery of therapeutics |
| EP4683665A1 (en) | 2023-03-23 | 2026-01-28 | ModernaTX, Inc. | Peg targeting compounds for delivery of therapeutics |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
| WO2025244134A1 (en) * | 2024-05-24 | 2025-11-27 | Fujifilm Corporation | Method to deliver a payload to cells, and lipid composition |
| WO2025261607A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particles, compositions and methods |
| WO2026027695A1 (en) | 2024-08-01 | 2026-02-05 | BioNTech SE | Compositions and methods |
| WO2026039780A1 (en) * | 2024-08-16 | 2026-02-19 | Modernatx, Inc. | Stable lipid nanoparticle compositions prepared without polymeric lipids and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| JP4764426B2 (ja) * | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| EP1969147B1 (en) | 2006-01-05 | 2014-07-30 | The Ohio State University Research Foundation | microRNA-based methods for the diagnosis of stomach cancer |
| US7670840B2 (en) | 2006-01-05 | 2010-03-02 | The Ohio State University Research Foundation | Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors |
| EP2522746B1 (en) | 2006-03-02 | 2014-11-12 | The Ohio State University Research Foundation | MicroRNA expression profile associated with pancreatic cancer |
| US20090131348A1 (en) | 2006-09-19 | 2009-05-21 | Emmanuel Labourier | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| US8252538B2 (en) | 2006-11-01 | 2012-08-28 | The Ohio State University | MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma |
| WO2008073915A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| US20090099034A1 (en) | 2007-06-07 | 2009-04-16 | Wisconsin Alumni Research Foundation | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers |
| CN101918594A (zh) | 2007-11-30 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 肺癌中外周血中的微rna表达特征谱和靶向 |
| EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| CA2717026A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| CA2740000C (en) * | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US9074206B2 (en) | 2008-11-13 | 2015-07-07 | Fudan University | Compositions and methods for micro-RNA expression profiling of colorectal cancer |
| EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| EP2427574A2 (en) | 2009-05-08 | 2012-03-14 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| US20130059015A1 (en) | 2010-03-11 | 2013-03-07 | H. Lee Moffitt Cancer Center & Research Institute | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| EP4321168A3 (en) * | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| EP2705370A2 (en) | 2011-05-06 | 2014-03-12 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| EP2718261B1 (en) * | 2011-06-08 | 2016-02-24 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing sirna activity |
| DK2732052T3 (en) | 2011-07-15 | 2017-02-20 | Leo Pharma As | Diagnostic microRNA profiling in cutaneous T cell lymphoma (CTCL) |
| EP2751292A4 (en) | 2011-09-01 | 2015-05-20 | Allegro Diagnostics Corp | METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES |
| US20140243240A1 (en) | 2011-10-26 | 2014-08-28 | Georgetown University | microRNA EXPRESSION PROFILING OF THYROID CANCER |
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| CN105142614A (zh) * | 2013-03-14 | 2015-12-09 | 迪克纳制药公司 | 用于配制阴离子试剂的方法 |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| EP3350333B2 (en) | 2015-09-17 | 2025-08-06 | ModernaTX, Inc. | Polynucleotides containing a stabilizing tail region |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| AU2017357758B2 (en) * | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3675817A1 (en) * | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US12109310B2 (en) * | 2018-06-28 | 2024-10-08 | Hadi Valadi | Exosome extracellular vesicles and methods of use |
| KR20210091120A (ko) * | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| HRP20240586T1 (hr) * | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CN118697900A (zh) * | 2019-01-31 | 2024-09-27 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| CA3169669A1 (en) * | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
-
2021
- 2021-08-06 EP EP21762299.2A patent/EP4192432A1/en active Pending
- 2021-08-06 WO PCT/US2021/044928 patent/WO2022032087A1/en not_active Ceased
- 2021-08-06 AU AU2021322310A patent/AU2021322310A1/en not_active Abandoned
- 2021-08-06 KR KR1020237007662A patent/KR20230167008A/ko not_active Withdrawn
- 2021-08-06 MX MX2023001567A patent/MX2023001567A/es unknown
- 2021-08-06 US US18/040,745 patent/US20230277457A1/en active Pending
- 2021-08-06 CA CA3190790A patent/CA3190790A1/en active Pending
- 2021-08-06 IL IL300404A patent/IL300404A/en unknown
- 2021-08-06 JP JP2023508048A patent/JP2023543963A/ja active Pending
- 2021-08-06 BR BR112023002071A patent/BR112023002071A2/pt not_active Application Discontinuation
- 2021-08-06 TW TW110129190A patent/TW202220637A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022032087A1 (en) | 2022-02-10 |
| BR112023002071A2 (pt) | 2023-05-02 |
| EP4192432A1 (en) | 2023-06-14 |
| TW202220637A (zh) | 2022-06-01 |
| KR20230167008A (ko) | 2023-12-07 |
| JP2023543963A (ja) | 2023-10-19 |
| US20230277457A1 (en) | 2023-09-07 |
| IL300404A (en) | 2023-04-01 |
| CA3190790A1 (en) | 2022-02-10 |
| AU2021322310A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009410A (es) | Metodos de preparacion de nanoparticulas lipidicas. | |
| MX2023001567A (es) | Metodos de preparacion de nanoparticulas lipidicas. | |
| EP4427739A3 (en) | Methods of preparing lipid nanoparticles | |
| Zheng et al. | Ultrasound-augmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death | |
| WO2022066898A3 (en) | Methods of producing extracellular vesicles | |
| MX2021011242A (es) | Conjugados de vesícula extracelular y usos de estos. | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| PH12022550112A1 (en) | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes | |
| SG10201908354VA (en) | Riluzole prodrugs and their use | |
| MX2020002348A (es) | Métodos de elaboración de nanopartículas lipídicas. | |
| EP3741362A3 (en) | Surface-modified mesoporous silica nanoparticle for blood-brain barrier penetration, tumor targeting and cancer metastasis treatment, methods of production and uses thereof | |
| MY157661A (en) | Bendamustine pharmaceutical compositions | |
| Ouyang et al. | Metronomic doses of temozolomide enhance the efficacy of carbon nanotube CpG immunotherapy in an invasive glioma model | |
| MX354702B (es) | Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral. | |
| GB0814302D0 (en) | Compounds and methods | |
| EP4272551A3 (en) | Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors | |
| WO2023104114A3 (en) | Rna formulations and lipids | |
| WO2022119883A3 (en) | Lipid nanoparticle compositions containing monoester cationic lipids | |
| WO2023028165A3 (en) | Tumor-associated calcium signal transducer 2 (tacstd2) antibody-maytansine conjugates and methods of use thereof | |
| MX2022005086A (es) | Anticuerpos anti-cd73 inmunomoduladores y usos de estos. | |
| EP4512816A3 (en) | Tlr7 agonists | |
| AR123171A1 (es) | Métodos para preparar nanopartículas lipídicas | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| MX2024012319A (es) | Conjugado anticuerpo-fármaco que comprende anticuerpo contra transductor de señal de calcio asociado a tumor 2 (trop2) humano y uso de este | |
| JP6957289B2 (ja) | 美白化粧料組成物 |